XML 24 R13.htm IDEA: XBRL DOCUMENT
v3.22.1

SHAREHOLDERS' EQUITY | 6 Months Ended
--- | ---
Feb. 28, 2022
SHAREHOLDERS' EQUITY [Abstract] |
SHAREHOLDERS' EQUITY | NOTE 7 – SHAREHOLDERS’ EQUITY The Company reserved 1.6 million shares of common stock for issuance to employees and directors pursuant to the Company’s 2014 Equity Incentive Plan (2014 Equity Plan). As of February 28, 2022 and August 31, 2021, there were 889,576 and 974,965 shares available for grant under the 2014 Equity Plan. Prior to the effective date of the 2014 Equity Plan, the Company granted options and stock awards to eligible participants under its 2004 Incentive Plan (2004 Incentive Plan), which expired on April 11, 2014. No additional awards may be granted pursuant to the 2004 Incentive Plan. The following table summarizes the combined stock option activity for the 2004 Incentive Plan and 2014 Equity Plan for the three months ended February 28, 2022:
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Number of Options |  | Weighted Average Exercise Price |  | Weighted Average Remaining Contractual Term |  | Approximate Aggregate Intrinsic Value (in thousands)
Outstanding at August 31, 2021 |  | 714,500 | ​ | $ | 7.80 |  | 6.1 | ​ | $ | 5,107
Granted |  | 105,000 | ​ | $ | 13.37 |  |  | ​ |  |
Exercised |  | (58,167) | ​ | $ | 7.67 |  |  | ​ |  |
Forfeited / Expired | ​ | (3,333) | ​ | $ | 10.45 | ​ | ​ | ​ | ​ | ​
Outstanding at February 28, 2022 |  | 758,000 | ​ | $ | 8.58 |  | 5.1 | ​ | $ | 2,639
​ |  |  | ​ |  |  |  |  | ​ |  |
Options exercisable at February 28, 2022 |  | 525,002 | ​ | $ | 7.41 |  | 4.9 | ​ | $ | 2,330
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ On January 12, 2022, the Company’s six non-employee Board members were each granted 2,000 shares of unrestricted stock. The fair market value of the unrestricted shares for share-based compensation expense is equal to the closing price of the Company's common stock on the date of grant of $13.23. There is no vesting requirement for the unrestricted stock grants and the Company recognized the full expense of $0.2 million during the three months ended February 28, 2022. ​ During the three and six months ended February 28, 2022, the Company had net settlement exercises of stock options, whereby the optionee did not pay cash for the options exercised but instead received the number of shares equal to the difference between the exercise price and the market price on the date of exercise. During the three months ended February 28, 2022, net settlement exercises resulted in 17,422 shares being issued and 21,578 options being cancelled in settlement of the shares issued. During the six months ended February 28, 2022, net settlement exercises resulted in 23,889 shares being issued and 28,278 options being cancelled in settlement of shares issued. During the three and six months ended February 28, 2022, the Company issued 6,000 shares of common stock upon the exercise of stock options, with an exercise price of $5.66, where the option holder used cash to exercise the options. ​ On January 13, 2021, the Company’s six non-employee Board members were each granted 2,000 shares of unrestricted stock. The fair market value of the unrestricted shares for share-based compensation expense is equal to the closing price of the Company's common stock on the date of grant of $11.33. There is no vesting requirement for the unrestricted stock grants and the Company recognized the full expense of $0.1 million during the three months ended February 28, 2021. ​ During the three and six months ended February 28, 2021, the Company had net settlement exercises of stock options, whereby the optionee did not pay cash for the options but instead received the number of shares equal to the difference between the exercise price and the market price on the date of exercise. During the three months ended February 28, 2021, net settlement exercises resulted in 3,159 shares being issued and 3,341 options being cancelled in settlement of shares issued. During the six months ended February 28, 2021, net settlement exercises resulted in 15,277 shares being issued and 9,223 options being cancelled in settlement of shares issued. ​ The following table summarizes the combined activity and value of non-vested options under the 2004 Equity Plan and 2014 Incentive Plan as for the three months ended February 28, 2022:
​ | ​ | ​ | ​ | ​ | ​
​ |  | Number of Options |  | Weighted Average Grant Date Fair Value
Non-vested options outstanding at August 31, 2021 |  | 218,333 | ​ | $ | 4.04
Granted |  | 105,000 | ​ | $ | 5.16
Vested |  | (87,002) | ​ | $ | 4.21
Forfeited |  | (3,333) | ​ | $ | 4.21
Non-vested options outstanding at February 28, 2022 |  | 232,998 | ​ | $ | 4.47
(a) | All non-vested options are expected to vest.
For the three months ended February 28, 2022 and 2021, the Company recorded $0.3 million and $0.2 million of stock-based compensation expense, which includes the amounts expensed related to the unrestricted stock granted to the Company’s Board members. For the six months ended February 28, 2022 and 2021, the Company recorded $0.4 million and $0.3 million of stock-based compensation expense, which includes the amounts expensed related to the unrestricted stock granted to the Company’s Board members. At February 28, 2022, the Company had unrecognized compensation expenses totaling $0.8 million relating to non-vested options that are expected to vest. The weighted-average period over which these options are expected to vest is approximately two and a half years.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration